Pages that link to "Q34322552"
Jump to navigation
Jump to search
The following pages link to A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528 (Q34322552):
Displaying 24 items.
- Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors (Q27693185) (← links)
- Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer? (Q28085104) (← links)
- Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. (Q33418555) (← links)
- The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC). (Q33437650) (← links)
- Development of second-generation VEGFR tyrosine kinase inhibitors: current status. (Q34616440) (← links)
- Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis (Q35187896) (← links)
- Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analyses (Q35346839) (← links)
- Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress? (Q35667802) (← links)
- New molecular targeted therapies for advanced non-small-cell lung cancer. (Q35667806) (← links)
- Efflux transporter variants as predictors of drug toxicity in lung cancer patients: systematic review and meta-analysis. (Q36043023) (← links)
- Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? (Q36999705) (← links)
- VEGF pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a 2013 update (Q38148602) (← links)
- The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials (Q38263351) (← links)
- An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer (Q38525073) (← links)
- Anti-angiogenesis in Personalized Therapy of Lung Cancer (Q38669276) (← links)
- Targeting FGFR in Squamous Cell Carcinoma of the Lung (Q38690050) (← links)
- Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer. (Q38964908) (← links)
- Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer (Q39226762) (← links)
- Strategies targeting angiogenesis in advanced non-small cell lung cancer (Q41593429) (← links)
- The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials (Q45230734) (← links)
- Newly developed anti-angiogenic therapy in non-small cell lung cancer. (Q52668159) (← links)
- Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients (Q57784764) (← links)
- VEGFR-TKIs combined with chemotherapy for advanced non-small cell lung cancer: A systematic review (Q64237947) (← links)
- Safety of combining vascular endothelial growth factor receptor tyrosine-kinase inhibitors with chemotherapy in patients with advanced non-small-cell lung cancer: A PRISMA-compliant meta-analysis (Q92559327) (← links)